• Skip to primary navigation
  • Skip to main content
Rebiotix Logo

Rebiotix

Powerful Therapy Delivered

  • Home
  • About
    • Senior Management
    • Stool Donor Program
    • Careers and Employment
  • Our Therapy
    • The Human Microbiome
    • Microbiota Restoration Therapy
    • Clostridioides difficile Infection
    • The Future of Microbiome-Based Therapeutics
  • Clinical Trials
    • RBX2660 Clinical Trials
    • RBX7455 Clinical Evaluation
    • Physician-sponsored Studies
    • Patient Resources
    • Expanded Access Policy
  • Science
    • Congress Publications
    • Manuscripts and Whitepapers
    • Related Evidence
  • Media
    • Latest Press Releases
    • Frequently Asked Questions
    • “Rebiotix” in the News
    • Conferences
    • Media Tools
    • Presentations & Videos
    • Contacts
  • Contact Us
  • Show Search
Hide Search

A Prototype Biomarker for Microbiome Rehabilitation in Patients with Clostridium difficile Infections: Application to a Clinical Trial of a Lyophilized, Non-Frozen, Oral, Microbiota-Based Drug RBX7455

Ken Blount PhD, Courtney Jones BS, Sahil Khanna MBBS, Elena Deych MS, Bill Shannon PhD MBA

Download this poster (229 KB)

ASM Microbe 2018
June 7-11, 2018

Background

  • Recurrent Clostridium difficile infections (rCDI) are strongly associated with dysbiosis—disruption of a healthy intestinal microbiome
  • We have developed two forms of Microbiota Restoration Therapy™: RBX7455 is a first-of-its-kind room temperature stable, orally administered MRT; and RBX2660, a ready to use liquid suspension MRT
  • In a recent investigator-sponsored Phase 1 trial, RBX7455 was effective at preventing rCDI and restored a healthier microbiome among responding participants
  • Since quantitative markers have not been definitively confirmed a prototype MICROBIOME HEALTH INDEX™ (MHI™) to enable unidimensional quantitation of microbiome health and restoration
  • Here we report MHI data from an interim analysis of the Phase 1 trial of RBX7455 in the context of two previous clinical trials of RBX2660 for preventing rCDI

Phase I Clinical Trial of RBX7455

  • Prospective, single-center, open-label Phase I investigator-initiated trial (NCT02981316) that enrolled single- and multi-recurrent CDI patients
  • After successful resolution of enrolling CDI episode, antibiotics were discontinued 24-48 hours prior to first RBX7455 dose
  • Participants received 8 RBX7455 capsules per day for four days (Cohort 1) or two days (Cohort 2)
  • Success was defined as freedom from CDI recurrence 8 weeks after treatment
  • 9 of 10 participants responded in cohort 1
  • 8 of 10 participants responded in cohort 2

RBX2660 Trials

  • PUNCH CD2™ (NCT02299570): a randomized, double-blinded, placebo-controlled trial of RBX2660 for preventing rCDI and PUNCH Open Label™ (NCT02589847) an open-label controlled trial of RBX2660 for preventing rCDI
  • PUNCH CD2: 64% of multi-recurrent CDI participants treated with at least RBX2660 dose were recurrence free 8 weeks after treatment, compared to 45% of placebo-treated participants (p=.047)
  • PUNCH Open Label: 79% of multi-recurrent CDI participants treated with at least one RBX2660 dose were recurrence free 8 weeks after treatment, compared to 47% in historical control arm

Microbiome Analysis

  • 8 RBX7455 drug product samples and 84 participant stool samples were sequenced using a shotgun sequencing method
  • Relative taxonomic abundances at the class level were calculated from OTU data for each time, treatment, outcome group, and the mean and upper/lower confidence limits defined by fitting to a Dirichlet-multinomial distribution using maximum likelihood estimation.

MICROBIOME HEALTH INDEX™ (MHI™) Analysis

MHI as a potential diagnostic (view poster for graphs; PDF 229 KB)

Successful response to microbiota-based therapies RBX7455 and RBX2660 is associated with increased MHI.

  • RBX7455 and RBX2660 product MHI values are similar
  • Baseline participant MHI values are similar among the trials
  • Responder MHI values (30 days) are similar among the trials

Conclusions

  • Among rCDI trial participants, MHI increased sharply after RBX7455 and RBX2660 treatment, with a majority of responders above a defined diagnostic threshold
  • Pre- and post-treatment MHI data are consistent among three clinical trials of both RBX2660 and RBX7455, regardless of sequencing methods
  • Future efforts will focus on prospective evaluation of MHI as a clinical trial endpoint to confirm the robustness of the metric

Microbiota Restoration Therapy Abstracts, Microbiota Restoration Therapy Posters Abstracts, Posters

Interested in Becoming a Stool Donor? Learn More

Rebiotix

  • Copyright © 2022 Rebiotix, Inc.
  • A Ferring Company
  • Privacy Policy
  • Terms of Use
  • Sitemap
  • Contact Us

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Cookie settingsACCEPT
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT